法国雷恩大学Karin Tarte研究组发现，滤泡性淋巴瘤触发人类淋巴基质细胞的表型和功能重塑。这一研究成果于2021年6月23日在线发表在国际学术期刊《免疫》上。

研究人员通过结合流式细胞术、原位成像、RNA测序和功能测定来分析了扁桃体组织，并定义了三个不同的人类淋巴基质细胞（LSC）亚群。整合素CD49a标记的血管周围基质细胞表现出LSC前体和成纤维细胞网状细胞（FRC）的特征。滤泡树突细胞转录谱反映了对B细胞和非B细胞刺激的主动反应。因此，研究人员检查了B细胞刺激对滤泡性淋巴瘤（FL）中LSC的影响。FL B细胞主要与CD49a⁺FRC相互作用。

转录分析显示LSC在肿瘤坏死因子（TNF）和转化生长因子β（TGF-β）下游的原位重编程，包括趋化因子CCL19和CCL21的表达增加。这些研究结果定义了健康组织中的人类LSC群体，并揭示了LSC和恶性B细胞之间的双向交流，这可能在淋巴瘤中是可靶向的信号轴。

据介绍，LSC是免疫反应的重要组织者。

附：英文原文

Title: Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape

Author: Frédéric Mourcin, Léa Verdière, David Roulois, Rada Amin, Claire Lamaison, Vonick Sibut, Brice Thamphya, Céline Pangault, Céline Monvoisin, Sarah Huet, Marine Seffals, Sylvain Baulande, Fatima Mechta-Grigoriou, Patricia Legoix, Delphine Rossille, Marion Guirriec, Simon Léonard, Guillaume Cartron, Gilles Salles, Thierry Fest, Karin Tarte

Issue&Volume: 2021-06-23

Abstract: Lymphoid stromal cells (LSCs) are essential organizers of immune responses. We analyzedtonsillar tissue by combining flow cytometry, in situ imaging, RNA sequencing, and functional assays, defining three distinct human LSCsubsets. The integrin CD49a designated perivascular stromal cells exhibiting featuresof local committed LSC precursors and segregated cytokine and chemokine-producingfibroblastic reticular cells (FRCs) supporting B and T cell survival. The folliculardendritic cell transcriptional profile reflected active responses to B cell and non-Bcell stimuli. We therefore examined the effect of B cell stimuli on LSCs in follicularlymphoma (FL). FL B cells interacted primarily with CD49a+ FRCs. Transcriptional analyses revealed LSC reprogramming in situ downstream of the cytokines tumor necrosis factor (TNF) and transforming growth factorβ (TGF-β), including increased expression of the chemokines CCL19 and CCL21. Our findingsdefine human LSC populations in healthy tissue and reveal bidirectional crosstalkbetween LSCs and malignant B cells that may present a targetable axis in lymphoma.

DOI: 10.1016/j.immuni.2021.05.019

Source: https://www.cell.com/immunity/fulltext/S1074-7613(21)00225-9